• American Medical Directors Association (AMDA). Stroke management and prevention in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2005. 42 p. [83 references]

This is the current release of the guideline.

The guideline was developed by an interdisciplinary work group using a process that combined evidence- and consensus-based thinking.

• American Medical Directors Association (AMDA). Stroke management and prevention in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2005. 42 p. [83 references]

Not applicable: The guideline was not adapted from another source.

2005

American Medical Directors Association - Professional Association

Organizational participants included:

• American Association of Homes and Services for the Aging
• American College of Health Care Administrators
• American Geriatrics Society
• American Health Care Association
• American Society of Consultant Pharmacists
• National Association of Directors of Nursing Administration in Long-Term Care
• National Association of Geriatric Nursing Assistants
• National Conference of Gerontological Nurse Practitioners

American Medical Directors Association

Steering Committee

Naushira Pandya, MD, CMD, Project Chair

Steven Levenson, MD, CMD, Clinical Practice Committee Chair

Steering Committee Members: Donna Brickley, RN; Harlan Martin, R.Ph., CCP, FASCP; Lisa Cantrell, RN, C; Geri Mendelson, RN, CNAA, M.Ed, NHA; Charles Cefalu, MD, MS; Evvie F. Munley; Sandra Fitzler, RN; Jonathan Musher, MD, CMD; Joseph Gruber, RPh, FASCP, CGP; Mariann Piver, RNC,CDON/LTC; Larry Lawhorne, MD, CMD; Mary Tellis-Nayak RN, MSN; Steven Levenson, MD, CMD; Barbara Resnick, PhD, CRNP; Susan M. Levy, MD, CMD; William Simonson, Pharm.D., FASCP

Not stated

This is the current release of the guideline.

None available

This summary was completed by ECRI on June 29, 2005. The information was verified by the guideline developer on August 8, 2005. This summary was updated by ECRI on March 6, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin sodium). This summary was updated by ECRI Institute on September 7, 2007 following the revised U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin).

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For more information, please contact the American Medical Directors Association (AMDA) at (800) 876-2632.